For the first time in the history of HIV prevention, people at risk of infection can be protected with just two injections a year. The U.S. Food and Drug Administration has approved lenacapavir — brand name Yeztugo — as a pre-exposure prophylaxis (PrEP) option, making it the only HIV prevention drug with a twice-yearly dosing schedule. Clinical trial data showed it stopped transmission in more than 99.9% of participants, a figure that stunned even veteran researchers in the field.
At a glance
- Lenacapavir HIV prevention: Gilead Sciences developed the drug, a capsid inhibitor that disrupts HIV at multiple points in its lifecycle — a mechanism distinct from every existing oral PrEP option on the market.
- Clinical trial results: The PURPOSE 1 and PURPOSE 2 Phase 3 studies, published in the New England Journal of Medicine, showed the shot outperformed daily oral PrEP and recorded near-zero transmission across tens of thousands of participants.
- Global access commitments: Gilead has signed royalty-free licensing agreements with six generic manufacturers to supply affordable versions of the drug to 120 countries, with priority given to high-burden regions in sub-Saharan Africa, Southeast Asia, and the Caribbean.
How lenacapavir HIV prevention works
Most existing PrEP medications block HIV at a single point in its replication cycle. Lenacapavir works differently. It belongs to a class called capsid inhibitors, which interfere with the virus at multiple stages simultaneously — disrupting how it enters cells, how it replicates, and how new viral particles assemble.
This layered mechanism makes resistance harder to develop. It also enables the drug’s long-acting formulation. The twice-yearly schedule is not a marketing convenience — it is a direct result of how the compound behaves in the body over time, remaining at protective concentrations for roughly six months after each injection.
Researchers had been working toward this kind of long-acting injectable PrEP for years. The science of the drug and the science of adherence were always understood as connected problems. The World Health Organization recommended lenacapavir as an additional PrEP option in 2024 C.E., a step that opens pathways for inclusion in national HIV prevention programs worldwide.
Why the dosing schedule is the breakthrough
Daily oral PrEP has been available since 2012 C.E. and, when taken consistently, is highly effective. Consistency is the hard part.
Stigma, unreliable clinic access, the psychological weight of a daily reminder, economic instability, and the simple reality of busy lives all erode adherence over time. The communities carrying the heaviest HIV burden are often the same ones facing the most barriers to daily medication routines. UNAIDS has described lenacapavir as a potential turning point precisely because it removes most of those friction points at once.
No daily pill. No visible medication to explain to a partner or a parent. Far fewer clinic visits. A twice-yearly injection restructures the entire prevention experience — and in public health, structural simplification has historically driven adoption far more than incremental efficacy gains alone.
Who participated and why it matters
The PURPOSE 1 trial enrolled primarily cisgender women in sub-Saharan Africa — a population that accounts for a disproportionate share of new HIV infections globally and one that has historically been underrepresented in the clinical research that shapes global drug policy. Their participation in a trial designed around their specific risk profile is a meaningful part of how this drug came to exist.
Sub-Saharan Africa accounts for roughly two-thirds of all people living with HIV worldwide. The PURPOSE 1 results, published in the New England Journal of Medicine, showed zero HIV infections among participants receiving lenacapavir, compared to infections in the oral PrEP comparison group. That outcome, in a high-prevalence population, is what gave regulators the confidence to move quickly.
The access question that remains open
Gilead’s royalty-free licensing deals with six generic manufacturers are a real commitment. They are also not enough on their own. Generic production takes time to scale. Distribution infrastructure in high-burden regions is uneven. The U.S. list price for branded lenacapavir is high, and advocates have pressed Gilead — and governments — to ensure affordability extends beyond the 120 countries named in the licensing agreements.
Roughly 1.3 million new HIV infections occur globally each year. The gap between what is approved and what actually reaches the people who need it is where many medical advances stall. Programs like PEPFAR and multilateral partnerships with organizations including Gavi have historically helped bridge that gap for antiretrovirals and vaccines — similar mechanisms will almost certainly be needed here to translate this approval into meaningful population-level impact.
The drug does not solve the structural inequities that drive HIV transmission. What it does is give prevention programs a genuinely new tool — one that works through a different mechanism, lasts longer, and asks considerably less of the people using it. In global health, that combination is rare.
Read more
For more on this story, see: AP News
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Ghana establishes new marine protected area at Cape Three Points
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Marie-Louise Eta becomes first female head coach in men’s top-five European leagues
Female head coach Marie-Louise Eta made history on April 11, 2026, when Union Berlin appointed her as interim head coach — becoming the first woman ever to hold a head coaching position in any of men’s top-five European leagues. The Bundesliga club made the move after dismissing Steffen Baumgart, with five matches remaining and real relegation stakes on the line. Eta, 34, had served as assistant coach since 2023 and was already a familiar, trusted presence within the squad. This was no ceremonial gesture — she was handed a survival fight, which is precisely what makes the milestone significant. The…
-
Renewables hit 49% of global power capacity for the first time
Renewable energy capacity crossed a landmark threshold in 2025, with global installed power surpassing 5,100 gigawatts and representing 49% of all capacity worldwide for the first time in history. The International Renewable Energy Agency reported a single-year addition of 692 gigawatts, led overwhelmingly by solar power, which alone accounted for 75% of new renewable installations. Clean energy now represents 85.6% of all new power capacity added globally, signaling that the transition has moved from aspiration to economic reality. The milestone carries implications beyond climate — nations with strong renewable bases demonstrated measurably greater energy security amid ongoing geopolitical instability.
-
Global suicide rate has dropped nearly 40% since the 1990s
Global suicide rates have dropped nearly 40% since the early 1990s, falling from roughly 15 deaths per 100,000 people to around nine — one of modern public health’s most significant and underreported victories. This decline was driven by expanded mental health services, crisis intervention programs, and proven strategies like restricting access to lethal means. The progress spans dozens of countries, with especially sharp declines in East Asia and Europe. Critically, this trend demonstrates that suicide is preventable at a population level — making the case for sustained investment in mental health infrastructure worldwide.
